Antibe Therapeutics Releases Secondary Endpoint Data for Lead Drug
Antibe Therapeutics released positive secondary endpoint data from the recent Phase 2B Gastrointestinal safety study for its lead drug, ATB-346. These results are consistent with the primary endpoint data, previously released in March 2018.